secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001104659-24-097152
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager grants Novartis license to capsid for gene therapy; $15M upfront, up to $305M milestones
--------------------------------------------------------------------------------

- Novartis receives exclusive license to a capsid from Voyager's TRACER platform for a single gene target.
- One-time $15M fee paid upfront; Voyager eligible for $130M in development/regulatory/commercial milestones.
- Additional sales milestones up to $175M per product plus tiered mid- to high-single-digit royalties.
- Novartis' prior option rights for other targets expired as of September 3, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924097152/0001104659-24-097152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924097152/tm2423222d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-097152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer